Health / WORLD

Bracco reports 6 million global doses of VUEWAY gadopiclenol MRI contrast injection

Diagnostic imaging company Bracco announced that more than 6 million intravenous doses of VUEWAY (gadopiclenol) have been administered worldwide since its initial 2022 approval, following 2026 EU and U.S. pediatric extensions to term neonates and infants. The release also highlights the Max 3 injector and AiMIFY software, without disclosing product sales revenue.

Reading sizeSources ↓Share story ↗
Conceptual illustration of public health, research and connected data.Illustration
Symbolic illustration

Diagnostic imaging company Bracco announced in Princeton, New Jersey, on 20 November 2026 that more than 6 million doses of VUEWAY (gadopiclenol) intravenous injection have been administered worldwide. First approved by regulators in 2022, VUEWAY is a macrocyclic gadolinium-based contrast agent used in magnetic resonance imaging to detect and visualize lesions with abnormal vascularity across the central nervous system—including the brain, spine, and associated tissues—as well as the head, neck, thorax, abdomen, pelvis, and musculoskeletal system. While the 6-million-dose figure tracks cumulative global clinical utilization over a four-year period, the announcement does not disclose unit sales revenue, geographic dose breakdowns, or market-share percentages.

VUEWAY is formulated to deliver diagnostic contrast enhancement at a gadolinium dose of 0.05 millimoles per kilogram of body weight, which corresponds to half the standard 0.1 millimoles per kilogram dose used by conventional gadolinium-based contrast agents. According to Cosimo De Pinto, Executive Vice President of Marketing and Commercial Operations at Bracco Americas, the macrocyclic molecular design provides the highest relaxivity per gadolinium ion among U.S. Food and Drug Administration-approved gadolinium contrast agents with comparable indications, enabling lower cumulative gadolinium exposure for patients who require repeated imaging scans.

During 2026, regulatory authorities in both the European Union and the United States expanded the approved pediatric labeling of VUEWAY to cover term neonates and infants alongside older children and adults. Extending the indication to the youngest pediatric cohorts broadens hospital eligibility for low-dose contrast-enhanced magnetic resonance imaging, though the company's release does not report how many of the 6 million cumulative doses were administered to pediatric or neonatal patients.

Alongside the contrast agent milestone, Bracco highlighted two complementary hardware and software systems within its magnetic resonance imaging workflow portfolio. The first is the ulricheasyINJECT Max 3 (model XD 10180), a cable-free, closed-system, syringeless rapid-exchange magnetic resonance injector distributed by Bracco Diagnostics Inc. Featuring automatic air detection, particle filtration, and SafeConnect touch protection, the Max 3 injector received an expanded U.S. indication permitting its use with the multi-patient VUEWAY Imaging Bulk Package in addition to single-dose vials, prefilled syringes, and pharmacy bulk packages.

The second portfolio component highlighted by the company is AiMIFY, an artificial-intelligence software application developed in partnership with Subtle Medical. AiMIFY is designed to amplify existing contrast enhancement in post-contrast brain magnetic resonance images to assist radiologists in visualizing enhancing lesions, and was named Best New Radiology Software in AuntMinnie.com's 2026 Minnies Awards. Pairing a lower-dose macrocyclic agent with automated multi-dose injectors and post-processing software reflects an industry strategy to bundle contrast consumables with imaging department hardware and workflow software.

In its mandatory prescribing and safety disclosures, Bracco reiterated the class-wide boxed warning applicable to gadolinium-based contrast agents. VUEWAY is strictly contraindicated for intrathecal administration—which can cause fatal or severe reactions including coma, encephalopathy, and seizures—and carries a boxed warning for nephrogenic systemic fibrosis in patients with impaired drug elimination. The risk of nephrogenic systemic fibrosis is highest in patients with acute kidney injury or chronic, severe kidney disease defined by a glomerular filtration rate below 30 milliliters per minute per 1.73 square meters of body surface area.

Clinical trial safety data included in the prescribing summary note that gadolinium can be retained for months or years in bone, brain, skin, kidney, liver, and spleen tissue following administration, and that acute kidney injury requiring dialysis has occurred in patients with chronically reduced renal function. In clinical studies, the most common adverse reactions occurring at an incidence of 0.5 percent or higher were injection-site pain at 0.7 percent and headache at 0.7 percent, while post-marketing surveillance across gadolinium agents has recorded rare cases of acute pancreatitis within 48 hours of dosing, acute respiratory distress syndrome, pulmonary edema, and gadolinium-associated skin plaques.

Manufactured for Bracco Diagnostics Inc. by BIPSO GmbH in Singen, Germany, VUEWAY's passage beyond 6 million administered doses confirms sustained clinical adoption since its 2022 launch and 2026 neonatal label expansion. Evaluating the commercial impact of that milestone would require financial disclosures on contrast media revenue, hospital adoption rates for the Max 3 Imaging Bulk Package configuration, and clinical outcome studies comparing AI-amplified brain MRI against standard protocols.

Data

Key figures

Key reported figures

Selected figures transcribed from the cited primary source.

Cumulative VUEWAY (gadopiclenol) injection doses administered worldwide
≥6,000,000 doses
2026-11-20 · Observed
Clinical trial incidence of injection-site pain with VUEWAY
0.7 percent
2026-11-20 · Observed
Clinical trial incidence of headache with VUEWAY
0.7 percent
2026-11-20 · Observed
Methodology

Figures retain the source's stated period, scope and definitions. Announced targets, estimates and approximate figures are labeled by basis and qualifier. No missing value is inferred.

Updated:

Structured coverage

Subjects and places

Subject proposals

Geographic references

Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.

  • United States · Place role: Coverage · Place type: Country or area · Location precision: Regional
    Evidence
Taxonomy version: IPTC Media Topics 2026-Q2

Continue reading

Health

Johnson & Johnson reports Phase 4 STAR trial gains for TREMFYA in axial psoriatic arthritis

Johnson & Johnson announced on 20 November 2026 that TREMFYA met primary and major secondary endpoints at Week 24 in the 411-patient Phase 4 STAR study of axial psoriatic arthritis, reducing BASDAI scores and MRI-assessed sacroiliac inflammation versus placebo.

Johnson & Johnson, Phase 4 STAR Study Results for TREMFYA in Axial Psoriatic Arthritis5 min read Data included
Health

United Therapeutics completes first UThymoKidney xenotransplant in EXTEND trial

United Therapeutics announced on 20 November 2026 that surgeons at NYU Langone Health performed the first porcine thymokidney transplant in its EXTEND Phase 1/2/3 trial for end-stage renal disease. The investigational organ uses a single gene edit and porcine thymic tissue and remains unapproved.

United Therapeutics Corporation, First Transplant in EXTEND Clinical Trial of UThymoKidney5 min read Data included
Health

PAQ Therapeutics presents first Phase 1 clinical data for KRAS G12D degrader PT0253 at ENA 2026

PAQ Therapeutics reported on 20 November 2026 preliminary Phase 1 results for its selective KRAS G12D degrader PT0253 in advanced solid tumors, showing no dose-limiting toxicities across 10 to 750 mg and early responses in monotherapy and first-line pancreatic cancer.

PAQ Therapeutics, First Clinical Data for PT0253 KRAS G12D Degrader at ENA 20264 min read Data included